An exploratory analysis from the PREDATOR study of metastatic colorectal cancer (mCRC) patients undergoing surgical resection
Lonardi S et. all. Int. J. Mol. Sci. 2022, 23(19), 11529; https://doi.org/10.3390/ijms231911529
Background:
While several tests exist to detect molecular residual disease (MRD) in earlier stages of cancer, this study demonstrates FoundationOne®Tracker’s ability to detect ctDNA once metastatic lesions have been surgically removed from advanced cancers.[1,2]
Traditionally, carcinoembryonic antigen (CEA), a blood-based biomarker, has been measured as the standard of care for colorectal cancer (CRC) patients to assess disease status in the post-surgical surveillance setting. However, several studies have reported its limited clinical utility, with a sensitivity of predicting recurrence between 50–80%, and a high rate of false positives and negatives.[3,4,5,6]
Study Details:
In a new study published in the International Journal of Molecular Sciences, researchers establish the feasibility of ctDNA-based MRD detection in metastatic colorectal cancer (mCRC) patients undergoing surgical resection, using FoundationOne Tracker.[1]
The publication, titled “Comprehensive genomic profiling (CGP)-informed personalized molecular residual disease (MRD) detection: An exploratory analysis from the PREDATOR study of metastatic colorectal cancer (mCRC) patients undergoing surgical resection” demonstrates that tissue-informed post-operative MRD detection with FoundationOne Tracker is an emerging prognostic biomarker that is predictive of disease-free survival and overall survival in patients with resected mCRC.[2]
Why this matters:
This research demonstrates that ctDNA detection is more predictive of disease-free survival that CEA testing.[2]
Reference: Lonardi S et. all. Int. J. Mol. Sci. 2022, 23(19), 11529; https://doi.org/10.3390/ijms231911529
Read more in the International Journal of Molecular Sciences.
References
[1]
FoundationOne Tracker is currently only available for research use. It is not yet available for clinical use and is not FDA approved.[2]
Lonardi S et. all. Int. J. Mol. Sci. 2022, 23(19), 11529; https://doi.org/10.3390/ijms231911529[3]
Sorensen, C.G.; Karlsson, W.K.; Pommergaard, H.C.; Burcharth, J.; Rosenberg, J. The diagnostic accuracy of carcinoembryonic antigen to detect colorectal cancer recurrence—A systematic review. Int. J. Surg. 2016, 25, 134–144.[4]
Nicholson, B.D.; Shinkins, B.; Mant, D. Blood Measurement of Carcinoembryonic Antigen Level for Detecting Recurrence of Colorectal Cancer. JAMA 2016, 316, 1310–1311.[5]
Shinkins, B.; Nicholson, B.D.; Primrose, J.; Perera, R.; James, T.; Pugh, S.; Mant, D. The diagnostic accuracy of a single CEA blood test in detecting colorectal cancer recurrence: Results from the FACS trial. PloS ONE 2017, 12, e0171810.[6]
Litvak, A.; Cercek, A.; Segal, N.; Reidy-Lagunes, D.; Stadler, Z.K.; Yaeger, R.D.; Kemeny, N.E.; Weiser, M.R.; Pessin, M.S.; Saltz, L. False-positive elevations of carcinoembryonic antigen in patients with a history of resected colorectal cancer. J. Natl. Compr. Cancer Netw. 2014, 12, 907–91